Pfizer reaffirms transparency of COVID vaccine data

Pfizer (PFE) reaffirmed its commitment to transparently and consistently disclosing its research findings regarding its COVID-19 vaccine and to maintaining the integrity of those ongoing studies for all those it serves. Dr. Albert Bourla, Chairman and CEO, made the following statement: “The success of Operation Warp Speed and U.S. development of mRNA vaccines is a profound public health achievement. Under President Trump’s leadership, American innovation led the world, helping prevent economic collapse and saving more than 14 million lives globally. Operation Warp Speed restored consumer confidence, saved over $1 trillion in health care costs due to reductions in serious illness and avoidance of hospitalizations, and rapidly scaled up domestic production. This American leadership also delivered a new platform that may drive significant innovation in cancer research. Such an accomplishment would typically be worthy of the Nobel Peace Prize, given its significant impact. President Trump’s call for transparency is welcomed, and we remain deeply committed to that principle. Transparency has always been a cornerstone of trust, and we are dedicated to continuing to provide clear, factual data to the public. To date, data on Pfizer’s COVID-19 vaccine have appeared in over 600 peer-reviewed publications. In addition to the U.S. FDA, detailed data has been submitted to regulators in 130 countries, and, after thorough review and analysis, all approved the vaccine. Many nations, including the United Kingdom, Denmark, Israel, and Turkey, have gone on to generate real-world evidence through their vaccination programs, further validating the vaccine’s safety and effectiveness in everyday settings.” In response to President Trump’s request, the company provided a link to Pfizer’s website containing numerous published studies and updates on safety, immunogenicity, and efficacy data in “an open and accessible manner,” adding that it will post additional information and studies by the end of the month.